Brodalumab: First Global Approval

Overview

Journal Drugs

Specialty Pharmacology

Date 2016 Sep 1

PMID 27577550

Citations 15

Authors

Sarah L Greig

Affiliations

Soon will be listed here.

Abstract

Brodalumab (Lumicef(®)) is a human monoclonal immunoglobulin G antibody that is being developed by Kyowa Hakko Kirin in Japan, where it has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma. Brodalumab binds with high affinity to interleukin (IL)-17 receptor A, thereby inhibiting several pro-inflammatory cytokines from the IL-17 family. Regulatory applications for brodalumab in plaque psoriasis are also under review in the USA, EU and Canada. This article summarizes the milestones in the development of brodalumab leading to this first approval for the treatment of psoriasis.

Citing Articles

Aberrant Chitinase 3-Like 1 Expression in Basal Cells Contributes to Systemic Sclerosis Fibrosis.

Wang X, Ye T, Huang J, Hu F, Huang C, Gu B Adv Sci (Weinh). 2024; 12(6):e2310169.

PMID: 39686726 PMC: 11809421. DOI: 10.1002/advs.202310169.

Brodalumab Is Effective for Psoriasis Patients with Difficult-To-Treat Body Regions: Results from an Observational Clinical Study.

Dauth S, Foldenauer A, Hallmann K, Kunz C, Konig A, Haferland I Dermatology. 2024; 241(1):80-91.

PMID: 39504944 PMC: 11793098. DOI: 10.1159/000542348.

Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial.

Okubo Y, Kobayashi S, Murakami M, Sano S, Kikuta N, Ouchi Y Am J Clin Dermatol. 2024; 25(5):837-847.

PMID: 38954226 PMC: 11358179. DOI: 10.1007/s40257-024-00876-x.

EGFR is a potential dual molecular target for cancer and Alzheimer's disease.

Choi H, Jeong Y, Kim J, Hoe H Front Pharmacol. 2023; 14:1238639.

PMID: 37601068 PMC: 10433764. DOI: 10.3389/fphar.2023.1238639.

The Interleukine-17 Cytokine Family: Role in Development and Progression of Spondyloarthritis, Current and Potential Therapeutic Inhibitors.

Davydova A, Kurochkina Y, Goncharova V, Vorobyeva M, Korolev M Biomedicines. 2023; 11(5).

PMID: 37238999 PMC: 10216275. DOI: 10.3390/biomedicines11051328.

References

Endres C, Salinger D, Kock K, Gastonguay M, Martin D, Klekotka P . Population pharmacokinetics of brodalumab in healthy adults and adults with psoriasis from single and multiple dose studies. J Clin Pharmacol. 2014; 54(11):1230-8. DOI: 10.1002/jcph.334. View

Papp K, Reid C, Foley P, Sinclair R, Salinger D, Williams G . Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial. J Invest Dermatol. 2012; 132(10):2466-2469. DOI: 10.1038/jid.2012.163. View

Kivelevitch D, Menter A . Use of brodalumab for the treatment of psoriasis and psoriatic arthritis. Immunotherapy. 2015; 7(4):323-33. DOI: 10.2217/imt.14.113. View

Papp K, Leonardi C, Menter A, Ortonne J, Krueger J, Kricorian G . Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012; 366(13):1181-9. DOI: 10.1056/NEJMoa1109017. View

Salinger D, Endres C, Martin D, Gibbs M . A semi-mechanistic model to characterize the pharmacokinetics and pharmacodynamics of brodalumab in healthy volunteers and subjects with psoriasis in a first-in-human single ascending dose study. Clin Pharmacol Drug Dev. 2016; 3(4):276-83. DOI: 10.1002/cpdd.103. View

Russell C, Rand H, Bigler J, Kerkof K, Timour M, Bautista E . Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014; 192(8):3828-36. DOI: 10.4049/jimmunol.1301737. View

Farahnik B, Beroukhim K, Abrouk M, Nakamura M, Zhu T, Singh R . Brodalumab for the Treatment of Psoriasis: A Review of Phase III Trials. Dermatol Ther (Heidelb). 2016; 6(2):111-24. PMC: 4906115. DOI: 10.1007/s13555-016-0121-x. View

Papp K, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C . A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016; 175(2):273-86. DOI: 10.1111/bjd.14493. View

Mease P, Genovese M, Greenwald M, Ritchlin C, Beaulieu A, Deodhar A . Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis. N Engl J Med. 2014; 370(24):2295-306. DOI: 10.1056/NEJMoa1315231. View

10.

Lebwohl M, Strober B, Menter A, Gordon K, Weglowska J, Puig L . Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. N Engl J Med. 2015; 373(14):1318-28. DOI: 10.1056/NEJMoa1503824. View

11.

Campa M, Mansouri B, Warren R, Menter A . A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatol Ther (Heidelb). 2015; 6(1):1-12. PMC: 4799039. DOI: 10.1007/s13555-015-0092-3. View

12.

Mease P, Genovese M, Mutebi A, Viswanathan H, Chau D, Feng J . Improvement in Psoriasis Signs and Symptoms Assessed by the Psoriasis Symptom Inventory with Brodalumab Treatment in Patients with Psoriatic Arthritis. J Rheumatol. 2016; 43(2):343-9. DOI: 10.3899/jrheum.150182. View

13.

Nakagawa H, Niiro H, Ootaki K . Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: Efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2015; 81(1):44-52. DOI: 10.1016/j.jdermsci.2015.10.009. View

14.

Umezawa Y, Nakagawa H, Niiro H, Ootaki K . Long-term clinical safety and efficacy of brodalumab in the treatment of Japanese patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2016; 30(11):1957-1960. DOI: 10.1111/jdv.13785. View